Drug Development Consulting BidCo ApS - CVR: 42287067

2023, DKK

02.05.2024

Bruttoresultat

2.320'

Primær drift

-622'

Årets resultat

-9.381'

Aktiver

121''

Kortfristede aktiver

7.927'

Egenkapital

70.212'

Afkastningsgrad

-1 %

Soliditetsgrad

58 %

Likviditetsgrad

163 %

Resultat

02.05.2024

Årsrapport	2023 02.05.2024	2022 16.06.2023	2021 31.05.2022
Nettoomsætning
Bruttoresultat	2.320.000	3.760.000	-4.389.000
Resultat af primær drift	-622.000	1.822.000	-5.320.000
Indtægter af kapitalandele (tilknyttede og associerede)	0	-11.717.000	-9.326.000
Finansielle indtægter	138.000	0	0
Finansieringsomkostninger	-3.817.000	-2.673.000	-1.457.000
Andre finansielle omkostninger	0	0	0
Resultat før skat	-10.330.000	-12.568.000	0
Resultat	-9.381.000	-11.831.000	-15.752.000
Forslag til udbytte	0	0	-200.000

Aktiver

02.05.2024

Årsrapport	2023 02.05.2024	2022 16.06.2023	2021 31.05.2022
Kortfristede varebeholdninger	0	0	0
Kortfristede tilgodehavender fra salg og tjenesteydelser	6.510.000	1.317.000	2.614.000
Likvider	1.417.000	16.680.000	1.894.000
Kortfristede aktiver	7.927.000	17.997.000	4.508.000
Immaterielle aktiver og goodwill	0	0	0
Finansielle anlægsaktiver	112.742.000	106.310.000	125.474.000
Materielle aktiver	0	0	0
Langfristede aktiver	112.742.000	106.310.000	125.474.000
Aktiver	120.669.000	124.307.000	129.982.000

Aktiver

02.05.2024

Passiver

02.05.2024

Årsrapport	2023 02.05.2024	2022 16.06.2023	2021 31.05.2022
Forslag til udbytte	0	0	200.000
Egenkapital	70.212.000	71.831.000	70.809.000
Hensatte forpligtelser	0	0	0
Langfristet gæld til banker	0	48.310.000	0
Anden langfristet gæld	0	0	2.600.000
Leverandører af varer og tjenesteydelser	0	0	0
Kortfristede forpligtelser	4.867.000	4.166.000	5.543.000
Gældsforpligtelser	0	0	0
Forpligtelser	0	0	0
Passiver	120.669.000	124.307.000	129.982.000

Passiver

02.05.2024

Nøgletal

02.05.2024

Årsrapport	2023 02.05.2024	2022 16.06.2023	2021 31.05.2022
Afkastningsgrad	-0,5 %	1,5 %	-4,1 %
Dækningsgrad	Na.	Na.	Na.
Resultatgrad	Na.	Na.	Na.
Varelagerets omsætningshastighed	Na.	Na.	Na.
Egenkapitals-forretning	-13,4 %	-16,5 %	-22,2 %
Payout-ratio	Na.	Na.	-1,3 %
Gældsdæknings-nøgletal	-16,3 %	68,2 %	-365,1 %
Soliditestgrad	58,2 %	57,8 %	54,5 %
Likviditetsgrad	162,9 %	432,0 %	81,3 %

Resultat

02.05.2024

Gæld

02.05.2024

Årsrapport

02.05.2024

Nyeste:01.01.2023- 31.12.2023(offentliggjort: 02.05.2024)

Information om virksomhedens regnskabsklasse:The annual report of Drug Development Consulting BidCo ApS for 2023 has been prepared in accordance with the provisions in the Danish Financial Statements Act applying to reporting class C middle sized entities.

Oplysning om eventualaktiver:Contractual obligations and contingencies, etc. Other contingent liabilitiesThe company is jointly taxed with its parent company Drug Development Consulting Holdco ApS and is jointly and severally liable with other jointly taxed group enterprises for payment of income taxes for the income year 2021 and onwards as well as withholding taxes on interest, royalties and dividends falling due for payment. The company has under the loan facilities amounting to k. DKK 49. 000, issued and unconditionally an irrevocables guarantee as primary obligors for the loans.

Beretning

02.05.2024

Dato for ledelsens godkendelse af årsrapporten:2024-04-25

Ledelsespåtegning:Ledelsespåtegning

Statement by Management on the annual report

Identifikation af den godkendte årsrapport:Today, the Board of Directors and the Executive Board have discussed and approved the annual report of Drug Development Consulting BidCo ApS for the financial year 1 January ‑ 31 December 2023.

Management's review

Beskrivelse af virksomhedens væsentligste aktiviteter:Business reviewDrug Development Consulting BidCo ApS was established on 8 April 2021 and on 17 May 2021 Gilde Healthcare, a private equity company with headquarter in the Netherlands, acquired the KLIFO A/S (the KLIFO Group) through Drug Development Consulting BidCo ApS. Drug Development Consulting Bidco ApS is a management consultancy company for the KLIFO Group. KLIFO Group is a drug development consultancy with significant experience in partnering with biotech and pharmaceutical companies to advance their drug development projects. KLIFO offers cross functional consulting and operational solutions spanning all areas of strategic advises, regulatory affairs, CMC development, clinical research, pharmacovigilance, clinical trial supply and quality assurance. Over the past decade, KLIFO has grown to become an established and integrated drug development consultancy providing end to end expert capabilities, enabling our partners to maximize opportunity, mitigate risks, drive innovation and achieve efficient project advancement. In 2023, the biotech market, particularly in the Nordics, faced significant challenges exacerbated by a constrained funding environment post-COVID, coupled with heightened interest and market volatility. These factors notably affected KLIFO during the first half of 2023, resulting in a decline in activity level compared to 2022. To adapt to the new market situation, KLIFO made organizational adjustments throughout 2023. Looking forward, KLIFO is witnessing a rise in activity levels and order book, projecting a return to business growth in 2024.